Development of 111In-labeled porphyrins for SPECT imaging

Document Type : Original Article


1 Radiation Application School, Nuclear Science and Technology Research Institute (NSTRI), Iran

2 Nuclear Science and Technology Research Institute (NSTRI), Tehran, Iran,


Objectives: The aim of this research was the development of 111In-labeled porphyrins as possible radiopharmaceuticals for the imaging of tumors. Methods: Ligands, 5, 10, 15, 20-tetrakis (3, 5-dihydroxyphenyl) porphyrin) (TDHPP), 5, 10, 15, 20-tetrakis (4-hydroxyphenyl) porphyrin (THPP) and 5, 10, 15, 20-tetrakis (3,4-dimethoxyphenyl) porphyrin) (TDMPP) were labeled with 111InCl3 (produced from proton bombardment of natCd target) in 60 min at 80ºC. Quality control of labeled compounds was performed via RTLC and HPLC followed by stability studies in final formulation and presence of human serum at 37ºC for 48 h as well as partition coefficient determination. The biodistribution studies performed using tissue dissection and SPECT imaging up to 24h. Results: The complexes were prepared with >99% radiochemical purity (HPLC and RTLC), high stability in 48h. Partition coefficients (calculated as log P) for 111In-TDHPP, 111In-THPP and 111In-TDMPP were 0.88, 0.8 and 1.63 respectively. Conclusion: Due to urinary excretion with fast clearance for 111In-TDMPP, this complex is probably a suitable candidate for considering as a possible tumor imaging agent.


Main Subjects

1. Lang K, Mosinger J, Wagnerová D. Photophysical properties of porphyrinoid sensitizers noncovalently
bound to host molecules; models for photodynamic therapy. Coordination chemistry reviews. 2004;248:321‐50.
2. Bonnett R, Martı́nez G. Photobleaching of sensitisers used in photodynamic therapy. Tetrahedron. 2001;57:9513‐47.
3. Andrade SM, Costa S. Spectroscopic studies on the interaction of a water soluble porphyrin and two drug carrier proteins. Biophys J.2002;82:1607‐19.
4. Berenbaum M, Akande S, Bonnett R, Kaur H, Ioannou S, White R, et al. Meso‐Tetra (hydroxyphenyl) porphyrins, a new class of potent tumour photosensitisers with favourable selectivity. Br J Cancer. 1986;54:717.
5. Lambrechts SA, Aalders MC, Verbraak FD, Lagerberg JW, Dankert JB, Schuitmaker JJ. Effect of albumin on the photodynamic inactivation of microorganisms by a cationic porphyrin. J Photochem Photobiol B. 2005;79:51‐7.
6. Gantchev TG, Ouellet R, van Lier JE. Binding interactions and conformational changes induced by sulfonated aluminum phthalocyanines in human serum albumin. Arch Biochem Biophys. 1999;366:21‐30.
7. An W, Jiao Y, Dong C, Yang C, Inoue Y, Shuang S.Spectroscopic and molecular modeling of the binding of meso‐tetrakis (4‐hydroxyphenyl) porphyrin to human serum albumin. Dyes and Pigments. 2009;81:1‐9.
8. Allison BA, Pritchard PH, Levy JG. Evidence for low‐density lipoprotein receptor‐mediated uptake of benzoporphyrin derivative. Br J Cancer. 1994; 69: 833–9.
9. Rovers J, Saarnak A, Molina A, Schuitmaker J, Sterenborg H, Terpstra O. Effective treatment of liver metastases with photodynamic therapy, using the second‐generation photosensitizer meta‐tetra (hydroxyphenyl) chlorin (mTHPC), in a rat model. Br J Cancer. 1999;81:600‐8.
10. Hambright P, Fawwaz R, Valk P, McRae J, Bearden A. The distribution of various water soluble radioactive metalloporphyrins in tumor bearing mice. Bioinorg Chem. 1975;5:87‐92.
11. Whelan HT, Kras LH, Ozker K, Bajic D, Schmidt MH, Liu Y, et al. Selective incorporation  f111Inlabeled
PHOTOFRIN™ by glioma tissuein vivo. J Neurooncol. 1994;22:7‐13.
12. Bhalgat MK, Roberts JC, Mercer‐Smith JA, Knotts BD, Vessella RL, Lavallee DK. Preparation and biodistribution of copper‐67‐labeled porphyrins and porphyrin‐A6H immunoconjugates. Nucl Med Biol. 1997; 24:179‐85.
13. Subbarayan M, Shetty S, Srivastava T, Noronha O, Samuel A. Evaluation studies of technetium‐99mporphyrin (T3, 4BCPP) for tumor imaging. J Porphyrins Phthalocyanines. 2001;5:824‐8.
14. Kavali RR, Chul Lee B, Seok Moon B, Dae Yang S, Soo Chun K, Woon Choi C, et al. Efficient methods for the synthesis of 5‐(4‐[18F] fluorophenyl)‐10, 15, 20‐tris (3‐methoxyphenyl) porphyrin as a potential imaging agent for tumor. J Label Compd Radiopharm. 2005;48:749‐58.
15. Das T, Chakraborty S, Sarma H, Banerjee S. A novel [109Pd] palladium labeled porphyrin for possible use in targeted radiotherapy. Radiochimica Acta. 2008;96:427‐33.
16. Yamazaki K, Hirata S, Nakajima S, Kubo Y, Samejima N, Sakata I. Whole‐body Autoradiography of Tumor‐bearing Hamsters with a New Tumor Imaging Agent, Indium‐111‐labeled Porphyrin. Jpn J Cancer Res. 1988;79:880‐4.
17. Quastel M, Richter A, Levy J. Tumour scanning with indium‐111 dihaematoporphyrin ether. Br J
Cancer. 1990;62:885.
18. Sadeghpour H, Jalilian AR, Akhlaghi M, Kamalidehghan M, Mirzaii M. Preparation and Biodistribution of [111In]‐rHuEpo for
Erythropoietin Receptor Imaging. J Radioanal Nucl Chem. 2008; 278:117‐122.
19. Mirzaii M, Afarideh H, Haji‐Saied SM, Ardaneh K.Production of 111 In by irradiation of natural cadmium with deuterons and protons in NRCAM cyclotron. Energy (MeV). 1998; 6: 16.
20. Sangster J. Octanol‐water partition coefficients of simple organic compounds. Washington DC:
American Chemical Society and the American Institute of Physics for the National Institute of
Standards and Technology; 1989.
21. United States Pharmacopoeia 28, 2005, NF 23,p.1009.
22. United States Pharmacopoeia 28, 2005, NF 23,p.1895.
23. Bernard C. Chemistry of Metal Radionuclides (Rb,Ga, In, Y, Cu and Tc)